Immunotherapy

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Retrieved on: 
Wednesday, January 11, 2023
Immunotherapy, Conference, Šmíd, Mink, Patient, KOL, Therapy, Cancer, Pharmaceutical industry

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.

Key Points: 
  • NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.
  • Access to the live fireside chat is available at https://brileyoncology22.sequireevents.com/ .
  • Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations .
  • B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.

Allergist/Immunologist Misu Paul, MD to Join ENT and Allergy Associates, LLP In Bay Ridge and Dyker Heights Brooklyn, NY

Retrieved on: 
Wednesday, January 11, 2023
Otorhinolaryngology, Allergy, Teaching hospital, Internal medicine, Hindi, Asthma, American College of Allergy, Asthma and Immunology, Immunotherapy, American Board of Commissioners for Foreign Missions, Throat, American College, Ear, American Academy of Allergy, Asthma, and Immunology, Knowledge, Hives, Norwegian Asthma and Allergy Association, LLP, Patient, Baylor College of Medicine, American Academy, Atopic dermatitis, Allergist, Research, Audiology, Drug allergy, American Board of Internal Medicine, Dermatitis, Food allergy, Nose, Baylor University, The Stony Brook School, Immunology, Medical device, Adult, MD, Medicine

Dr. Paul is board certified by the American Board of Internal Medicine and the American Board of Allergy and Immunology.

Key Points: 
  • Dr. Paul is board certified by the American Board of Internal Medicine and the American Board of Allergy and Immunology.
  • Dr. Paul is active in the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.
  • In Bay Ridge, Dr. Paul will work side-by-side with otolaryngologists Ramez Habib, MD, Christopher Song, MD, and Wesley Davidson, MD.
  • In Dyker Heights, she will join otolaryngologists Leon Chen, MD and Wayne Chung, MD.

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Retrieved on: 
Wednesday, January 11, 2023
Potyvirus, Therapy, CMC, Immunotherapy, A549, Valo, Vaccine, Infection, A549 cell, Patient, Cancer, Doe, CDMO, GMP

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

Key Points: 
  • HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.
  • ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform.
  • Exothera brings expertise in adenovector and A549 cells with a deep knowledge of state-of-the-art manufacturing technology and DoE-based development tools.
  • This important work with Exothera will enable us to develop a large-scale manufacturing process for VALO-D102 to support our future clinical development plans and pave the way for future commercial-scale manufacturing.”

BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

Retrieved on: 
Tuesday, January 10, 2023
IND, Cell, University, Intellectual property, Therapy, Patent, New Drug Application, Immunotherapy, BCT, United States Patent and Trademark Office, Trial of the century, AON, TSX, FDA, Cancer, Hope, Biological patents in the United States, HLA, Patient, Phase II, Breast cancer, Pharmaceutical industry, 3D printing

BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with FDA guidance.

Key Points: 
  • BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with FDA guidance.
  • The patent will issue on January 24, 2023 as US Patent No.
  • Additionally, BriaCell was awarded an Australian patent (Patent No.
  • BriaCell currently holds multiple issued patents and pending patent applications to cover its whole-cell immunotherapy’s composition of matter and method of use worldwide.

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

Retrieved on: 
Tuesday, January 10, 2023
IND, Immunotherapy, Degenerative disease, SAB, Toxicity, Therapy, T1D, Patient, FDA, MD, Serum sickness, Pharmaceutical industry, Vaccine

SAB will submit the IND filing within approximately 12 months.

Key Points: 
  • SAB will submit the IND filing within approximately 12 months.
  • SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
  • As a fully-human polyclonal antibody therapeutic, SAB-142 may be administered multiple times without causing these immune-related adverse reactions, a desired factor when treating life-long diseases such as type 1 diabetes.
  • The study results showed that both SAB-142 and its active control, FDA-approved animal-derived polyclonal anti-thymocyte immunoglobulin, induced transient lymphodepletion confirming the SAB-142 mechanism of action.

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
IND, Luman Hamlin Weller, Non-Hodgkin lymphoma, Science, MHRA, Lymphoma, Therapy, Gilead Sciences, IKZF1, BTK, Biotechnology, Standby Equity Distribution Agreement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Safety, CLL, FDA, IKZF3, Immunotherapy, Head, ASH, Conference, Innovation, Lymphatic system, Food, Health care, Chronic lymphocytic leukemia, Society for Immunotherapy of Cancer, Patient, Cancer, SAN, Clinical trial, Sale, SITC, Annual general meeting, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in H2 2023 based on emerging clinical data and feedback from the U.S. Food and Drug Administration (FDA).
  • In addition, Nurix expects to define a dose for Phase 1b cohort expansion in H2 2023.
  • New drug candidate: Nurix expects to select a new targeted protein degrader development candidate in 2023.
  • Research milestones: Nurix expects to achieve substantial research collaboration milestones throughout 2023 from its existing collaborations with Gilead Sciences and Sanofi.

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

Retrieved on: 
Monday, January 9, 2023
IND, NSCLC, PTCL, Large-cell lung carcinoma, CTAS, AML, Stomach, Colorectal cancer, Acute myeloid leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Society, Neck, FDA, Macrophage, Immunotherapy, Infrared spectroscopy correlation table, Partnership, Cancer, NK, HL, Food, Patient, Society for Immunotherapy of Cancer, Genentech, Hodgkin lymphoma, EGFR, Roivant Sciences, CTA, SITC, PD-1, CD123, Head, Renal cell carcinoma, Pharmaceutical industry, Affimer

“We believe there is significant unmet need to help patients in these difficult cancer indications with limited treatment options and continue to make progress across our pipeline.

Key Points: 
  • “We believe there is significant unmet need to help patients in these difficult cancer indications with limited treatment options and continue to make progress across our pipeline.
  • Affimed expects to report data from all three ongoing AFM24 studies at scientific conferences in Q2/Q3 2023.
  • AFM24-101: Affimed continues to enroll patients in the expansion phase of the AFM24 monotherapy study at the RP2D.
  • Affimed is eligible for additional proceeds including pre-clinical milestones as well as milestones based on early regulatory achievements.

iTeos Provides Business Updates and Clinical Development Plans for 2023

Retrieved on: 
Monday, January 9, 2023
NSCLC, Large-cell lung carcinoma, Therapy, Immunotherapy, Multiple myeloma, Birth certificate, Tumor microenvironment, Partnership, Patient, Adenosine, GSK, Medical imaging, Pharmaceutical industry, Fine chemical, Vaccine

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.
  • In 2023, we will continue to progress our broad clinical plan against validated targets and benefit from informative readouts across the field.
  • “Leveraging our scientific expertise, drug development capabilities, financial resources, and our strong partnership with GSK, we are in an enviable position as we kick off 2023.
  • New clinical development program with the potential to fully reverse adenosine immune suppression, in combination with inupadenant, but also other standards of care.

SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

Retrieved on: 
Monday, January 9, 2023
Epitope, Immunotherapy, Clostridioides difficile (bacteria), Biotechnology, PST, MD, J. P. Morgan, Vaccine

Dr. Kropotova’s presentation, titled: Next Generation Biologics in Immunology: Solution for Complex Diseases, will discuss the latest innovations and treatment pathways in immunology, including an overview of SAB’s novel DiversitAb™ platform.

Key Points: 
  • Dr. Kropotova’s presentation, titled: Next Generation Biologics in Immunology: Solution for Complex Diseases, will discuss the latest innovations and treatment pathways in immunology, including an overview of SAB’s novel DiversitAb™ platform.
  • DiversitAb™ is the only platform in the world that produces fully-human, broadly neutralizing, polyclonal antibodies utilizing transchromosomic cows.
  • Dr. Kropotova will also present data from completed clinical trials that indicate SAB’s polyclonal antibody therapies can provide long-lasting efficacy against numerous highly mutating pathogens or multiple targets or pathways at once.
  • “SAB’s approach is to develop treatments designed to address multiple dysregulated pathways, multiple disease targets, and multiple epitopes in one powerful treatment,” said Dr. Kropotova.

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

Retrieved on: 
Monday, January 9, 2023
IND, PRAME, PIWIL1, NSCLC, ImmTAC, Circulating tumor DNA, HBV, Neoplasm, GI, RECIST, Immunotherapy, Autoimmunity, HIV, DNA, Pancreatic cancer, Infection, Conference, ESMO, Webcast, TCR, Patient, CD3, Single, Cancer, HLE, Endometrial cancer, HLA-A24, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Q4, IMC, Immunocore, EU

In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.

Key Points: 
  • In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
  • The IMC-F106C-101 trial is adaptive and enables combinations with standards-of-care including checkpoint inhibitors, chemotherapy, and tebentafusp.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023.
  • The Company plans to report data from the Single Ascending Dose portion of the Phase 1 HIV trial in 2023.